Our core services

PRMA Consulting are experts in pricing, reimbursement, and market access. We work in close partnership with our clients to deliver integrated and innovative solutions to market access.

Patient-reported outcomes

Strategies to optimize the generation of patient-centered outcomes data to support the value proposition to regulators, reimbursement agencies, and patients

Learn more

Real-world evidence

Quantitative research into treatment, disease burden, and resource use to inform multiple elements of the market access strategy

Learn more

Economic models & evidence synthesis

Development of methodologically robust economic models and evidence synthesis according to HTA agency requirements

Learn more

Pricing & reimbursement strategy

Primary and secondary research to understand the current and likely future landscape and inform the value proposition and P&R strategy

Learn more

Value message testing

Semi-quantitative iterative evaluation, refinement, and validation of value messages with payors and clinicians to maximize the product value proposition

Learn more

Personalized medicine

In-depth understanding of the complexities and challenges around market access for companion diagnostic–drug pairings

Learn more

PRMA conferences & events

We regularly host webinars and attend international conferences, meet us online or face to face to discuss your market access issues

View our events

PRMA Insights syndicated reports

Developed by industry-experienced experts, these reports provide in-depth understanding of current and future market access realities

Learn more

Features and events

We regularly host webinars, produce short videos, and write hot topics on issues that we consider to be of critical importance in market access

ESMO, Madrid 2014

Meet with our experts in Madrid this September to see where we can help with your market access issues

26 Sep, 2014 / Meet with us >>

Hot topic

Facing the challenge of co-dependent technology assessment in Australia

14 Jul, 2014 / Learn more >>

PRO Consultant Sarah Shingler joins our expert team

We are delighted to welcome Dr Sarah Shingler to our Patient-Centered Outcomes team, led by Dr Annabel Nixon.

04 Jun, 2014 / Learn more >>

ISPOR Amsterdam 2014

Meet with our experts to see where we can help with your market access issues

8 Nov, 2014 / Meet with us >>

2014 ASH Annual Meeting

Meet with our experts to see where we can help with your market access issues

6 Dec, 2014 / Meet with us >>

We are recruiting

We currently have numerous vacancies for the right canditates

03 Jun, 2014 / All vacancies >>

Whitepaper

Are you really prepared for benefit assessment under AMNOG?

03 Jun, 2014 / Download >>

Whitepaper

Will your PRO data help or hinder HTA of your asset?

03 Jun, 2014 / Download >>

Syndicated reports

PRMA Insights: Pricing and Reimbursement Success are key resources for planning your market access strategy

AMNOG syndicated report

AMNOG

PRMA Insights Focus: The Impact of AMNOG on Pricing & Reimbursement in Germany and Beyond

Learn more >>

Companion diagnostics in oncology syndicated report

Companion diagnostics

PRMA Insights: Market Access Success for Companion Diagnostic–Drug Pairings in Oncology

Learn more >>

NSCLC syndicated report

NSCLC

PRMA Insights: Pricing & Reimbursement Success in NSCLC

Learn more >>

Metastatic breast cancer syndicated report

Metastatic breast cancer

PRMA Insights: Pricing & Reimbursement Success in Metastatic Breast Cancer

Learn more >>

Renal cell carcinoma syndicated report

Renal cell carcinoma

PRMA Insights: Pricing & Reimbursement Success in Renal Cell Carcinoma

Learn more >>

Rheumatoid arthritis syndicated report

Rheumatoid arthritis

PRMA Insights: Pricing & Reimbursement Success in Rheumatoid Arthritis

Learn more >>

Psoriasis syndicated report

Psoriasis

PRMA Insights: Pricing & Reimbursement Success in Psoriasis

Learn more >>

COPD syndicated report

COPD

PRMA Insights: Pricing & Reimbursement Success in COPD

Learn more >>

"PRMA Consulting is the best consultancy we've worked with in every way – flexibility, responsiveness, adherence to timelines and quality of the work."
Head of Market Access, Health Economics, and Pricing – top-30 global pharmaceutical company